Purchase this article with an account.
V. Parier, K. Atmani, V. Le Tien, E. Souied, G. Coscas, G. Soubrane; Intravitreal Injections of Ranibizumab in Choroidal Newvessels of Pathologic Myopia After Failure of Photodynamic Therapy. Invest. Ophthalmol. Vis. Sci. 2008;49(13):334.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy of intravitreal injections of ranibizumab in the treatment of subfoveal choroidal newvessels complicating pathologic myopia after failure of photodynamic therapy.
Retrospective study of 10 eyes of 10 patients with subfoveal choroidal newvessels complicating pathologic myopia. Measurement of best corrected visual acuity, ophthalmic examination, fluorescein and infracyanin green angiography, optical coherence tomography (OCT) were performed before and after treatment. All patients had already received one or more photodynamic therapy without functional and anatomical effect. One or more intravitreal injections of ranibizumab were then administred every month. The treatment was halted in the absence of neovascular activity signs in angiography and exudation in OCT.
The average age of patients was 57 years. The initial visual acuity was between 20/320 and 20/40 (average 20/100). The average follow-up period was 6 months. Intravitreal injections of ranibizumab achieved an improvement or stabilization of visual acuity and angiographic signs in all eyes. In this serie, seven patients required a single injection of ranibizumab.
Intravitreal injections of ranibizumab help to stabilize choroidal newvessels of pathologic myopia and seem an interesting therapeutic after failure of photodynamic therapy.
This PDF is available to Subscribers Only